FDA recalls multiple blood pressure medications for potential cancer risk

The FDA announced an expansion of a recall involving the blood pressure medicine losartan. (Source: U.S. Food and Drug Administration)

(WOIO/Gray News) - Several blood pressure medications have been recalled after exposure that could pose a cancer risk.

Torrent Pharmaceuticals Limited announced Thursday it is expanding its recall for losartan potassium tablets and losartan potassium/hydrochlorothiazide tablets, after trace amounts of N-Methylnitrosobutyric acid (NMBA) was detected.

Torrent Pharmaceuticals Limited is recalling the following medications:

Losartan Potassium Tablets, USP 50mg, 1000 count

NDC: 13668-409-10
Batch No.: 4DU2E009
Expiration: 12/31/2020

Losartan Potassium Tablets, USP 100mg, 90 count

NDC: 13668-115-90
Batch No.: 4DU3E009
Expiration: 12/31/2020

Losartan Potassium Tablets, USP 100mg, 1000 count

NDC: 13668-115-10
Batch No.: 4DU3D018
Expiration: 02/28/2021

Losartan Potassium / Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count

NDC: 13668-116-90
Batch No.: BEF7D051
Expiration: 11/30/2020

Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count

NDC: 13668-118-90
Batch No.: 4P04D007
Expiration: 07/31/2020

Anyone with questions can contact Torrent Pharmaceuticals Limited at (800) 912-9561.

Copyright 2019 WOIO via Gray Television Group, Inc. All rights reserved.

Read the original version of this article at cleveland19.com.



 
Comments are posted from viewers like you and do not always reflect the views of this station. powered by Disqus